Search Results | Diabetes | American Diabetes Association

1-20 of 42

2 3

Sort by

Sort Order Select

Meeting Abstracts

301-OR: Effect of Vitamin D Supplementation on Insulin Sensitivity and Beta-Cell Function in Prediabetes

NEDA RASOULI, IRWIN BRODSKY, RANEE CHATTERJEE, SUN H. KIM, RICHARD E. PRATLEY, MYRLENE STATEN, JASON P. NELSON, ANASTASSIOS G. PITTAS, D2D RESEARCH GROUP

Diabetes 2021;70(Supplement_1):301-OR

DOI: https://doi.org/10.2337/db21-301-OR

Published: 01 June 2021

View article

Meeting Abstracts

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, CHRISTOPHER P. CANNON, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, WEICHUNG J. SHIH, JIE LIU, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):783-P

DOI: https://doi.org/10.2337/db21-783-P

Published: 01 June 2021

View article

Meeting Abstracts

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

SAMUEL DAGOGO-JACK, ROBERT FREDERICH, BERNARD CHARBONNEL, JIE LIU, CHRISTOPHER P. CANNON, HARRY SHI, DARREN K. MCGUIRE, DAVID CHERNEY, FRANCESCO COSENTINO, WEICHUNG J. SHIH, URSZULA MASIUKIEWICZ, IRA GANTZ, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):785-P

DOI: https://doi.org/10.2337/db21-785-P

Published: 01 June 2021

View article

Meeting Abstracts

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, DAVID CHERNEY, BERNARD CHARBONNEL, DARREN K. MCGUIRE, FRANCESCO COSENTINO, WEICHUNG J. SHIH, JIE LIU, ROBERT FREDERICH, JAMES P. MANCUSO, ANNASWAMY RAJI, IRA GANTZ

Diabetes 2021;70(Supplement_1):786-P

DOI: https://doi.org/10.2337/db21-786-P

Published: 01 June 2021

View article

Meeting Abstracts

664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence

VANITA R. ARODA, ROBERT BAUER, ALUN L. DAVIES, ESKIL B. KREINER, PETER J. LIN, RICHARD E. PRATLEY, STEPHEN C. BAIN

Diabetes 2021;70(Supplement_1):664-P

DOI: https://doi.org/10.2337/db21-664-P

Published: 01 June 2021

View article

Meeting Abstracts

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

JURIS J. MEIER, RIKKE AGESEN, LARS BARDTRUM, ALICE Y. CHENG, SRIKANTH DEENADAYALAN, EDUARD MONTANYA, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):668-P

DOI: https://doi.org/10.2337/db21-668-P

Published: 01 June 2021

View article

Meeting Abstracts

647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

MATTHEW CAPEHORN, ANDREI-MIRCEA CATARIG, OFIR FRENKEL, CHARLOTTE HINDSBERGER, MICHEL MARRE, HERMIONE PRICE, RICHARD E. PRATLEY

Diabetes 2021;70(Supplement_1):647-P

DOI: https://doi.org/10.2337/db21-647-P

Published: 01 June 2021

View article

Meeting Abstracts

638-P: A Novel, Long-Acting Dual Agonist for GIPR/GLP-1R, HISHS-2001, Demonstrates Effects on HbA1c and Weight Loss in the db/db Mouse Model of Type 2 Diabetes

VINOD S. BURADE, ADOLFO GARCIA-OCANA, RICHARD E. PRATLEY, GUY A. RUTTER, TINA VILSBØLL, BERNARD THORENS, RAJAMANNAR THENNATI

Diabetes 2021;70(Supplement_1):638-P

DOI: https://doi.org/10.2337/db21-638-P

Published: 01 June 2021

View article

Meeting Abstracts

661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program

RICHARD E. PRATLEY, VANITA R. ARODA, CHARLOTTE HINDSBERGER, YASEMIN KOSE, MARGIT KALTOFT, ESTEBAN JODAR

Diabetes 2021;70(Supplement_1):661-P

DOI: https://doi.org/10.2337/db21-661-P

Published: 01 June 2021

View article

Meeting Abstracts

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, BERNARD CHARBONNEL, SAMUEL DAGOGO-JACK, RICHARD E. PRATLEY, WEICHUNG J. SHIH, MARIO MALDONADO, ANNPEY PONG, IRA GANTZ, ROBERT FREDERICH, JAMES P. MANCUSO, URSZULA MASIUKIEWICZ, CHRISTOPHER P. CANNON

Diabetes 2021;70(Supplement_1):796-P

DOI: https://doi.org/10.2337/db21-796-P

Published: 01 June 2021

View article

Meeting Abstracts

791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

RICHARD E. PRATLEY, SAMUEL DAGOGO-JACK, BERNARD CHARBONNEL, DAVID CHERNEY, FRANCESCO COSENTINO, DARREN K. MCGUIRE, MARGARET N. ESSEX, PHILIP L.S. JONES, JIE LIU, INGRID A. ADAMSONS, DAVID LAWRENCE, WEICHUNG J. SHIH, CHRISTOPHER P. CANNON

Diabetes 2021;70(Supplement_1):791-P

DOI: https://doi.org/10.2337/db21-791-P

Published: 01 June 2021

View article

Meeting Abstracts

926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

MARK ESPELAND, RICHARD E. PRATLEY, JULIO ROSENSTOCK, TAKASHI KADOWAKI, YUTAKA SEINO, BERNARD ZINMAN, NIKOLAUS MARX, DARREN K. MCGUIRE, KNUT R. ANDERSEN, MICHAELA MATTHEUS, ANNETT KELLER, ODD ERIK JOHANSEN

Diabetes 2020;69(Supplement_1):926-P

DOI: https://doi.org/10.2337/db20-926-P

Published: 01 June 2020

View article

Meeting Abstracts

927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4

RICHARD E. PRATLEY, ROBERT BAUER, SILVIO E. INZUCCHI, KAMLESH KHUNTI, ESKIL B. KREINER, PETER N. LAURSEN, JURIS J. MEIER

Diabetes 2020;69(Supplement_1):927-P

DOI: https://doi.org/10.2337/db20-927-P

Published: 01 June 2020

View article

Meeting Abstracts

2016-P: Bariatric Surgery May Improve Glucose Control among Patients with Type 1 Diabetes

FRANCESCO VENDRAME, ANNA CASU, RICHARD E. PRATLEY, PETER CALHOUN

Diabetes 2020;69(Supplement_1):2016-P

DOI: https://doi.org/10.2337/db20-2016-P

Published: 01 June 2020

View article

Meeting Abstracts

2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes

ANNA R. KAHKOSKA, JOHN B. BUSE, SIGNE HARRING, INGRID HOLST, FILIP K. KNOP, KAJSA KVIST, RICHARD E. PRATLEY

Diabetes 2020;69(Supplement_1):2160-PUB

DOI: https://doi.org/10.2337/db20-2160-PUB

Published: 01 June 2020

View article

Journal Articles

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

William G. Tharp, Dhananjay Gupta, Olga Sideleva, Carolyn F. Deacon, Jens J. Holst, Dariush Elahi, Richard E. Pratley

Diabetes 2020;69(2):146–157

DOI: https://doi.org/10.2337/db18-1163

Published: 22 November 2019

View article

Includes: Supplementary data

Meeting Abstracts

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

RICHARD E. PRATLEY, ASLAM AMOD, SOREN T. HOFF, TAKASHI KADOWAKI, ILDIKO LINGVAY, MICHAEL A. NAUCK, KAREN BOJE PEDERSEN, TRINE SAUGSTRUP, JURIS J. MEIER, FOR THE PIONEER 4 INVESTIGATORS

Diabetes 2019;68(Supplement_1):55-OR

DOI: https://doi.org/10.2337/db19-55-OR

Published: 01 June 2019

View article

Meeting Abstracts

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):53-OR

DOI: https://doi.org/10.2337/db19-53-OR

Published: 01 June 2019

View article

Meeting Abstracts

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):1001-P

DOI: https://doi.org/10.2337/db19-1001-P

Published: 01 June 2019

View article

Meeting Abstracts

1000-P: Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7

RICHARD E. PRATLEY, VANITA R. ARODA, THEIS GONDOLF, THOMAS HANSEN, ILDIKO LINGVAY, JOERG LUEDEMANN, TRINE VANG SKJOETH, ADIE VILJOEN

Diabetes 2019;68(Supplement_1):1000-P

DOI: https://doi.org/10.2337/db19-1000-P

Published: 01 June 2019

View article

2 3

NARROW

301-OR: Effect of Vitamin D Supplementation on Insulin Sensitivity and Beta-Cell Function in Prediabetes

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

638-P: A Novel, Long-Acting Dual Agonist for GIPR/GLP-1R, HISHS-2001, Demonstrates Effects on HbA1c and Weight Loss in the db/db Mouse Model of Type 2 Diabetes

661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4

2016-P: Bariatric Surgery May Improve Glucose Control among Patients with Type 1 Diabetes

2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

1000-P: Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7

Email alerts

Journals

Books

News

Other

About

Resources

Email alerts

Journals

Books

News

Other

About

Resources

This Feature Is Available To Subscribers Only